17962201

Source:http://linkedlifedata.com/resource/pubmed/id/17962201

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0000768, umls-concept:C0030705, umls-concept:C0040130, umls-concept:C0278678, umls-concept:C0332293, umls-concept:C1516119
pubmed:issue	2
pubmed:dateCreated	2008-2-4
pubmed:abstractText	Sorafenib is an orally bioavailable vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal cell carcinoma (RCC). Sunitinib, also a VEGFR inhibitor, induces biochemical hypothyroidism in 85% of metastatic RCC patients, the majority of whom have signs or symptoms of hypothyroidism. Hence, the incidence of thyroid function test (TFT) abnormalities in patients with metastatic RCC receiving sorafenib was investigated.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/sorafenib
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1569-8041
pubmed:author	pubmed-author:BukowskiRR, pubmed-author:DreicerRR, pubmed-author:ElsonPP, pubmed-author:GarciaJJ, pubmed-author:IoachimescuA GAG, pubmed-author:MekhailTT, pubmed-author:RiniB IBI, pubmed-author:TamaskarII, pubmed-author:WoodLL
pubmed:issnType	Electronic
pubmed:volume	19
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	265-8
pubmed:meshHeading	pubmed-meshheading:17962201-Administration, Oral, pubmed-meshheading:17962201-Adult, pubmed-meshheading:17962201-Aged, pubmed-meshheading:17962201-Aged, 80 and over, pubmed-meshheading:17962201-Benzenesulfonates, pubmed-meshheading:17962201-Carcinoma, Renal Cell, pubmed-meshheading:17962201-Chemotherapy, Adjuvant, pubmed-meshheading:17962201-Cohort Studies, pubmed-meshheading:17962201-Dose-Response Relationship, Drug, pubmed-meshheading:17962201-Drug Administration Schedule, pubmed-meshheading:17962201-Female, pubmed-meshheading:17962201-Follow-Up Studies, pubmed-meshheading:17962201-Humans, pubmed-meshheading:17962201-Hypothyroidism, pubmed-meshheading:17962201-Kidney Neoplasms, pubmed-meshheading:17962201-Male, pubmed-meshheading:17962201-Middle Aged, pubmed-meshheading:17962201-Neoplasm Metastasis, pubmed-meshheading:17962201-Pyridines, pubmed-meshheading:17962201-Retrospective Studies, pubmed-meshheading:17962201-Risk Assessment, pubmed-meshheading:17962201-Thyroid Function Tests
pubmed:year	2008
pubmed:articleTitle	Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
pubmed:affiliation	Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA. tamaski@ccf.org
pubmed:publicationType	Journal Article